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Spleen tyrosine kinase (Syk) is a cytoplasmic tyrosine 
kinase of 72 kDa and a member of the ZAP70 (ζ-chain-
associated protein kinase of 70 kDa)/Syk family of the 
non-receptor-type protein tyrosine kinases (PTKs) [1,2] 
and contains two SRC homology 2 (SH2) domains and a 
kinase domain [3]. Syk is expressed in most hemato-
poietic cells, including B cells, immature T cells, mast 
cells, neutrophils, macrophages, and platelets [1,3,4], and 
is important in signal transduction in these cells [2,5].
Syk plays an important role in signal transduction 
initiated by the classic immunoreceptors, including B-cell 
receptors (BCRs), Fc receptors, and the activating natural 
killer receptors [3,6,7]. Syk is associated mainly with 
ITAM (immunoreceptor tyrosine-based activation motif)-
dependent pathways and aﬀ  ects early development and 
activation of B cells, mast cell degranulation, neutrophil 
and macrophage phagocytosis, and platelet activation 
[1,3,4]. Functional abnormalities of these cells are 
invariably associated with both autoimmune and allergic 
diseases. Although there have been many exciting 
develop  ments in the treatment of these diseases, there 
are still serious limitations of the eﬃ   cacy of the used 
drugs as they are associated with the development of 
serious side eﬀ  ects. Because of the central role of Syk in 
signaling processes not only in cells of the adaptive 
immune response but also in additional cell types known 
to be involved in the expression of tissue pathology in 
autoimmune, autoinﬂ   ammatory, and allergic diseases, 
Syk inhibition has attracted considerable interest for 
further development. In this review, we will provide a 
brief account of the role of Syk signaling in various cell 
types and will summarize preclinical and clinical studies, 
which point to the therapeutic usefulness of Syk 
inhibition.
2. Syk in cell function
2.1. Syk and lymphocytes
Th  e function of Src-family kinases and Syk kinases in 
immunoreceptor signaling pathways is well known 
(Figure  1) [6]. After receptor engagement, Src-family 
kinases phosphorylate the ITAMs of immunoreceptors 
and this results in the recruitment and activation of Syk 
[6,7]. BCR- and FcR-deﬁ  ned dual-phosphorylated ITAMs 
recruit Syk through interaction with their tandem SH2 
domains, and this triggers kinase activation and down-
stream signaling [4,8].
Because the development of B and T cells requires 
intact antigen receptor-mediated signal transduction, Syk 
deﬁ  ciency leads to a complete absence of mature B cells, 
and ZAP70 deﬁ   ciency results in severe T-cell defects 
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pro-B cells into pre-B cells [9]. Although it was previously 
thought that BCR signaling was mediated via Syk and 
T-cell receptor (TCR) signaling via ZAP70, recent data 
have shown that ZAP70 has a role in B-cell development 
and Syk is important in pre-T cell signaling (Figure 2) 
[11,12]. It appears that Syk and ZAP70 have overlapping 
roles in early lymphocyte development [11,12].
For the transmission of BCR-mediated cell signaling 
events, subsequent activation of diﬀ  erent types of PTKs, 
including Syk, is required [13]. BCR aggregation can 
directly stimulate activation of pre-associated Syk, result-
ing in tyrosine phosphorylation of Igα-Igβ ITAMs 
[6,14,15]. Th  is phosphorylation leads to recruitment of 
additional Syk. Subsequently, recruited Syk is activated 
by Src-PTK-dependent transphosphorylation and by 
autophosphorylation [6,14]. Th  erefore, Syk is necessary 
for BCR-mediated tyrosine phosphorylation and signal 
transduction [6,15].
2.2. Syk and phagocytes
FcγR, one of the classic immunoreceptors, typically 
engages Syk [3,7,16,17], and Syk-deﬁ  cient murine macro-
phages display defective phagocytosis [7,16]. After FcγR 
engagement, ITAMs in the receptor are phosphorylated 
by Src-family kinases, resulting in the recruitment and 
activation of Syk. As a result, Syk-mediated phosphory-
lation of several adaptor proteins causes activation of 
downstream pathways, which execute phagocytosis. Syk 
is also important in complement-mediated phagocytosis 
resulting from the binding of C3bi-coated particles to 
complement receptor 3 [3,17]. Downstream of Syk, the 
signal involves Vav and RhoA to generate contractile 
forces, which result in the engulfment of the phago-
cytosed particles [3,17,18].
2.3. Syk and mast cells
FcεRI, the high-aﬃ     nity surface receptor for IgE, is 
expressed on the surface membrane of mast cells, and 
crosslinking of receptor-bound IgE by multivalent 
antigen starts the activation of mast cells by promoting 
the aggregation of FcεRI [19,20]. Degranulation and 
cytokine release occur after the activation signal starts 
the cascade [20]. Th   ese events contribute to the develop-
ment and continuation of allergic inﬂ  ammation.  Syk 
plays an important role in the development of signal 
transduction events initiated after FcεRI aggregation 
[2,21], mast cell activation, degranulation, and cytokine 
production (Figure 3) [22,23]. All of these facts point to 
the conclusion that Syk inhibition might be an attractive 
target for preventing allergen-induced diseases.
2.4. Syk and platelets
Th  ere are three platelet surface molecules, which, upon 
engagement, initiate Syk-mediated activation of SLP76 
(SH2 domain-containing leukocyte proteins 76) and 
phospholipase Cγ2 (Figure 4) [24,25]: (a) Platelet/mega-
caryo  cyte lineage cells express the platelet-speciﬁ  c integrin 
αIIbβ3 on their surface and this is required for normal 
hemostasis [3]. Syk mediates outside-in signaling by 
αIIbβ3 integrin on platelets [26,27]. Th   e mechanism of Syk 
activation by αIIbβ3 integrin was reported to require the 
ITAM-containing FcγIIA molecule [26]. (b) Glyco  protein 
VI (GPVI), a major collagen receptor of platelets, is an 
FcγR-related receptor and is closely associated with FcαRs 
[24]. Collagen activates the FcγR-associated recep  tor GPVI 
on platelets and triggers Syk activation in an ITAM-
dependent way [24,28]. SLP76, a Syk substrate, is required 
for arterial thrombus formation [28]. (c) Platelet agonists 
like rhodocytin and podoplanine activate the receptor C-
type lectin-like receptor 2 (CLEC2), which recruits Syk to 
the phosphorylated tyrosine in the CLEC2 ITAMs [4,28].
2.5. Syk in vascular development
Syk is required for the separation of lymphatic vessels in 
the general circulation [9,29]. Syk-deﬁ   cient mice die 
because blood ﬁ  lls the lymphatic vessels [29]. Probably, 
Syk activation together with platelet activation and 
aggregation play a role in lymphatic vessel development 
and their separation from blood vessels [4,9].
Figure 1. Structure of spleen tyrosine kinase (Syk) protein. Syk includes two tandem SH2 domains and a tyrosine kinase domain. Interdomain 
A is between the two SH2 domains, and interdomain B is between the tyrosine kinase domain and C-terminal SH2 domain. ITAM, immunoreceptor 
tyrosine-based activation motif; SH2, Src homology 2.
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N
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Osteoclasts are multinucleated cells that degrade bone 
by releasing proper enzymes. Syk has been claimed to 
have a role in osteoclast diﬀ  erentiation and osteoclast 
function [3,4]. Although FcγR is associated with 
osteoblast-osteo  clast interactions, DAP12 (DNAX-
activating protein of molecular mass 12 kDa) is the 
responsible protein for relaying an osteoblast-
independent signal [30,31]. Syk, which is downstream of 
DAP12 and FcγR, is required for osteoclast development 
Figure 2. Spleen tyrosine kinase (Syk)-mediated signaling in B-cell receptor (BCR) and T-cell receptor (TCR). Upon engagement of BCR or 
TCR, Syk or ZAP70 is recruited to plasma membrane receptors. Activated Syk/ZAP70 phosphorylates ITAM tyrosines. Signal transduction is initiated 
by phosphorylation of ITAM tyrosines. ITAM, immunoreceptor tyrosine-based activation motif; SH2, Src homology 2; ZAP70, ζ-chain-associated 
protein kinase of 70 kDa.
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Figure 3. FcεR crosslinking by allergen involves spleen tyrosine kinase (Syk)-mediated signaling transduction. Allergen binding to IgE 
bound to FcεR on mast cell initiates Lyn phosphorylation of the receptor and activation of Syk. Signaling events lead to mast cell degranulation, 
eicosanoid mediator synthesis, and cytokine production. FcεR, Fc receptor ε-chain; SH2, Src homology 2.
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Page 3 of 11Figure 4. Spleen tyrosine kinase (Syk)-mediated signal transduction in platelets. Signal transduction pathways are mediated through αIIbβ3 
integrin/FcγRIIA, CLEC-2, and GPVI/FcRγ. GPVI and αIIbβ3 use ITAM, whereas CLEC2 uses atypical ITAM. These three pathways of Syk activation 
result in platelet activation through SLP76 and PLCγ2. CLEC2, C-type lectin-like receptor 2; FcRγ, Fc receptor γ-chain; GPVI, glycoprotein VI; ITAM, 
immunoreceptor tyrosine-based activation motif; PLCγ2, phospholipase Cγ2; SH2, Src homology 2; SLP76, SH2 (Src homology 2) domain-containing 
leukocyte protein 76.
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Page 4 of 11and function (Figure 5) [30,32]. DAP12 phosphorylation 
recruits Syk through its SH2 domain, leading to 
autophosphorylation. Phosphorylated Syk associates 
with cytoskeleton network and actin ring formation [3]. 
In addition, it was reported that Syk plays a role in the 
process of osteolysis. Syk, therefore, repre  sents an 
attractive therapeutic target to mitigate increased 
osteoclastic activity in arthritis.
2.7. Syk and fi  broblasts
Fibroblast-like synoviocytes (FLSs) represent a signiﬁ  cant 
component of the synovial lining and contribute to the 
lubrication and preservation of the joint. In rheumatoid 
arthritis (RA), FLSs expand in numbers, acquire immune 
cell features, produce proinﬂ   ammatory cytokines and 
enzymes, and contribute to the inﬂ  ammatory  process 
and the eventual destruction of the joint. A number of 
studies have claimed a role for Syk in the function of FLSs 
[33,34]. Syk activation is important in tumor necrosis 
factor-alpha (TNFα)-induced cytokine and metallo-
protein  ase (MMP) production by RA FLSs [33]. Syk also 
plays an important role in TNFα-induced c-Jun N-
terminal kinase (JNK) activation in FLSs [33]. Th   is is an 
important event as in the future Syk inhibition may be 
used to supplement the therapeutic eﬀ   ect of TNF 
inhibition in patients who do not display suﬃ   cient 
response to TNF blockade. Activation of Syk by TNFα 
causes the activation of the protein kinase Cδ/JNK/c-Jun 
signaling pathway and this is important for the secretion 
of a critical cytokine, interleukin-32 (IL-32), by RA FLSs 
[34].
3. Syk inhibition therapy in autoimmune 
and allergic infl  ammatory diseases
Although the exact mechanisms of action remain 
unclear, Syk inhibitors have claimed encouraging 
therapeutic results in the treatment of patients with 
allergy, auto  immune diseases, or B-cell lineage 
malignancies [23,35,36]. R406, an orally available active 
metabolite of the prodrug R788 (fostamatinib), is a 
competitive Syk inhibitor [37,38]. Th  e selectivity for 
R406 in inhibiting Syk is limited as it may inhibit 
additional kinases and non-kinase targets. Among those 
targets are FMS-related tyrosine kinases 3 (FLT3), Lck, 
and Janus kinase 1 (JAK1) and JAK3, which may also be 
involved in the expression of autoimmune pathology 
[4]. Th  ese non-Syk targets may enhance the clinical 
value of R406 in the treatment of autoimmune diseases 
as JAK inhibitors have been con  sidered for the 
treatment of arthritis. R112 is another Syk inhibitor 
formulated for intranasal use [39] and has a rapid eﬀ  ect 
and quickly inhibits mast cell activation. Additional Syk 
inhibitors with less speciﬁ  city include piceatannol and 
BAY 61-3606 [40,41].
3.1. Syk inhibition in arthritis
Despite enormous advances in the treatment of RA, a 
signiﬁ  cant number of patients either fail to respond to 
treatment or develop signiﬁ  cant side eﬀ  ects. Based on a 
number of laboratory ﬁ   ndings and preclinical studies, 
including the fact that RA synovium displays increased 
amounts of phosphorylated Syk compared with osteo-
arthritis synovium [33], signiﬁ  cant  eﬀ   ort is currently 
being devoted to determine whether Syk inhibition can 
be used to treat patients with RA (Table 1).
3.1.1. Animal arthritis models and Syk inhibition
Strong preclinical studies point to the therapeutic poten-
tial of Syk inhibition. Syk-deﬁ  cient bone marrow murine 
chimeras do not allow the development of arthritis 
following the injection of arthritogenic K/BxN serum 
[42], suggesting the importance of hematopoietic cell 
Syk-dependent signaling in the development of arthritis. 
Administration of R406 reduced clinical arthritis in two 
antibody-induced arthritis models (K/BXN serum and 
collagen antibody). In addition, R406 suppressed bone 
erosions detected by radiography, pannus formation, and 
synovitis in these animal models [37]. It was also ob-
served that the expression of Syk in synovial tissues 
corre  lated with the levels of inﬂ  ammatory cell inﬁ  ltrates 
in the joints and was virtually undetectable in R406-
treated mice subjected to collagen-induced arthritis in 
rats [38]. In addition, Syk inhibition reduced synovial 
ﬂ   uid cytokine levels and cartilage oligomeric matrix 
protein in serum in these animals [38]. R406 was also 
found to limit an Arthus reaction in mice [37] and rats 
[38] and reverse passive Arthus reaction in murine 
chimeras with Syk-deﬁ  cient hematopoietic cells [43,44]. 
Th  is  eﬀ  ect is probably due to the suppression of immune-
complex-mediated inﬂ   ammation by inhibiting the Fc 
receptor signaling.
3.1.2. Human studies
After a small phase I study [45] in which clinical eﬃ   cacy 
of the R788 Syk inhibitor in patients with RA was not 
associated with serious side eﬀ  ects, a 12-week, random-
ized, placebo-controlled trial in which active RA patients 
who were also receiving methotrexate (MTX) were 
enrolled was carried out [46]. Twice-daily oral doses of 
100 and 150 mg of R788 were demonstrated to be signi  ﬁ  -
cantly superior to placebo and 50 mg twice a day of R788. 
Interestingly, the clinical eﬀ   ect was noted as early as 
1 week after the initiation of treatment. Patients receiv  ing 
100 and 150 mg R788 achieved excellent ACR20 
(American College of Rheumatology 20% improvement 
criteria) (65, 72%), ACR50 (49, 57%), and ACR70 (33, 
40%) responses. Also, signiﬁ   cant reductions in serum 
IL-6 and MMP-3 levels were noted within the ﬁ  rst week 
of treatment. Diarrhea and other gastrointestinal adverse 
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elevation in transaminase level were the reported major 
side eﬀ  ects.
In the follow-up study, 100 and 150 mg (twice daily) of 
R788 were compared with placebo at 6 months in 457 
active RA patients who were MTX incomplete respon-
ders [47]. Th   e ACR20 response was achieved in 66% and 
57% of patients in the 100 and 150 mg groups, respec-
tively, compared with 35% in the placebo group. Both 
R788 dosing regimens achieved statistical signiﬁ  cance 
compared with placebo at the sixth month. In this study, 
the onset of clinical eﬀ  ect was again rapid with maximum 
improvement achieved by week 6 and maintained 
through  out the study. Th   e most common side eﬀ  ect was 
reversible and dose-dependent diarrhea. Transient 
neutro  penia, hypertension, and elevation of liver function 
tests were also recorded.
Another randomized placebo-controlled phase II study 
was conducted in 219 RA patients who had failed 
treatment with at least one biologic agent [48]. Patients 
received either 100 mg (twice daily) of R788 or placebo. 
ACR20 response and magnetic resonance imaging (MRI) 
images of the hands and wrists were evaluated 3 months 
later. Th  ere was no statistical diﬀ  erence in the ACR20 
response between the two groups. However, a signiﬁ  cant 
decrease in erythrocyte sedimentation rate and C-reac-
tive protein and improvement in synovitis and osteitis 
scores on MRI were observed in the R788 group 
compared with the placebo group.
3.2. Syk inhibition in lupus animal models
In systemic lupus erythematosus (SLE), the FcγR-Syk 
associates with the TCR in lieu of the zeta-chain ZAP70 
[49]. Th  is rewiring of the TCR has been claimed to 
account, at least partly, for the overactive T-cell pheno  type 
observed in SLE [35]. In addition, the pathogenesis of SLE 
has been associated with B-cell activation in which Syk 
may play an important role. Th  erefore, Syk inhibition 
therapy was used in lupus animal models (Table 2).
Long-term (24 to 34 weeks) administration of R788 to 
lupus-prone NZB/NZW mice before and after disease 
onset [50] resulted in delayed onset of proteinuria and 
renal dysfunction, decreased kidney inﬁ  ltrates,  and 
prolonged survival in these mice. Although antibody 
titers were minimally aﬀ  ected, a dose-dependent reduc-
tion in the numbers of CD4+ activated T cells expressing 
high levels of CD44 or CD69 in spleens from R788-
treated mice was noted. Arthus responses were also 
reduced in NZB/NZW mice pretreated with R788. Also, 
a Syk inhibitor was reported to reduce the severity of 
established antibody-mediated experimental glomerulo-
nephritis in rats [51].
Treatment of lupus-prone MRL/lpr and BAX/BAK 
mice with R788 not only prevented the development of 
skin and renal pathology but also treated established 
disease [52]. Syk inhibition reduced splenomegaly and 
lymphadenopathy and other immune parameters. Th  e 
fact that Syk inhibition suppresses SLE in at least three 
lupus-prone mice suggests that Syk inhibition in patients 
with SLE may be of clinical value.
3.3. Syk inhibition in allergic diseases
Mainstay therapy for allergic diseases remains avoidance 
of allergens and allergen-speciﬁ   c immunotherapy [23]. 
However, allergen avoidance and immunomodulation 
therapies are usually impractical, complex, and time-
consuming [23]. Targeting activation of mast cells to 
prevent release of mediators represents an important 
treatment alternative [20,39,52,53]. An eﬀ  ec  tive way to 
inhibit the production and release of all mast cell 
Table 1. Spleen tyrosine kinase inhibition therapy in arthritis animal models and patients with rheumatoid arthritis
Reference  Drug  Duration  Model or disease  Outcome
Braselmann   R406  14 days, twice  Collagen-induced arthritis, K/BXN  Improved clinical scores, histopathology, and radiography
et al. [37]    a day, orally  arthritis model 
Pine et al.   R406  18 days, twice  Collagen-induced arthritis in rats  Suppressed clinical arthritis, bone erosions, pannus
[38]    a day, orally     formation, and synovitis
Weinblatt   R406  12 weeks, 100 or  Active RA patients who were  R788 (100 mg twice a day): 
et al. [46]    150 mg twice a day,   incomplete responders to MTX  ACR20, 50, and 70 responses (65%, 49%, and 33%)
    orally     R788 (150 mg every day): 
        ACR20, 50, and 70 responses (72%, 57%, and 40%)
Weinblatt   R788  6 months, 100 or  Active RA patients who were  R788 (100 mg twice a day): 
et al. [47]    150 mg twice a day,   incomplete responders to MTX  ACR20, 50, and 70 responses (66%, 43%, and 28%) 
    orally    R788 (150 mg every day): 
        ACR20, 50, and 70 responses (57%, 32%, and 14%)
Genovese   R788  3 months, 100 mg  Active RA patients who failed  R788 (100 mg twice a day): 
et al. [48]    twice a day, orally   biologic agents  ACR20 response (39%). 
        Response rate was not diff  erent from that of placebo.
ACR20, American College of Rheumatology 20% improvement criteria; ACR50, American College of Rheumatology 50% improvement criteria; ACR70, American 
College of Rheumatology 70% improvement criteria; MTX, methotrexate; RA, rheumatoid arthritis.
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by blocking the FcRε with biologics [20,23]. Alterna  tively, 
targeting the intracellular signaling cascade may 
represent an attractive approach. Appropriately, protein 
tyrosine kinases such as Syk, Lyn, and Btk have been 
directly implicated in IgE-dependent mast cell activation 
and have been suggested as targets for therapeutic 
intervention [39-41]. Syk represents the most attractive 
target because studies with mast cells derived from Syk-
deﬁ  cient indicated mice showed that Syk is important in 
the activation of mediators of degranulation, eicosanoid, 
and cytokine production [23,39]. Syk inhibition therapies 
in allergic diseases are summarized in Table 3.
3.3.1. Animal allergic disease models and Syk inhibition
Seow and colleagues [40] examined the eﬀ  ect of piceatan-
nol, a Syk inhibitor, on ovalbumin-induced anaphylactic 
contraction of isolated guinea pig bronchi and release of 
histamine and peptidoleuketrienes in vitro. Piceatannol 
pretreatment slightly suppressed peak anaphylactic 
bronchial contraction but facilitated relaxation of the 
contracted bronchi. Piceatannol did not inhibit direct 
histamine-, leukotriene D4-, or KCl-induced bronchial 
contraction or revert an existing anaphylactic bronchial 
contraction but did signiﬁ   cantly prevent ovalbumin-
induced release of both histamine and peptidoleuko-
trienes from lung fragments. But piceatannol did not 
inhibit exogenous arachidonic acid-induced release of 
peptidoleukotrienes from lung fragments. In an antigen-
induced airway inﬂ  ammation model in rodents, the Syk 
inhibitor BAY 61-3606 blocked both degranulation and 
lipid mediator and cytokine synthesis in mast cells and 
suppressed antigen-induced passive coetaneous reaction, 
bronchoconstriction, bronchial edema, and airway 
inﬂ  ammation [41].
R406 inhibited pulmonary eosinophlia, goblet cell 
meta  plasia, and airway hyper-responsiveness (AHR), 
which developed in BALB/c mice exposed to aerosolized 
1% ovalbumin for 10 consecutive days [20]. In addition, 
treatment with R406 suppressed the presence of eosino-
phils and lymphocytes and IL-13 in broncho  alveolar 
lavage ﬂ  uid. Suppression of Syk in bone marrow-derived 
dendritic cells was considered important in the suppres-
sion of AHR. Th  is preclinical information has justiﬁ  ed 
attempts to determine whether Syk inhibition may have 
clinical value.
3.3.2. Human allergic diseases and Syk inhibition
Syk inhibition has tried in patients suﬀ  ering of allergic 
disorders to determine whether it mitigates clinical 
manifestations. A nasal allergen challenge study in volun-
teers with allergic rhinitis showed that one intranasal 
dose of R112 is clinically safe and signiﬁ  cantly reduces 
the level of prostaglandin D2, a key mediator of allergic 
nasal congestion, but not histamine and tryptamine 
levels [54]. In this 2-day, multiple-dose, double-blind, 
placebo-controlled clinical study with seasonal allergic 
rhinitis patients, R112 signiﬁ  cantly decreased the global 
clinical symptom score compared with placebo. Each 
individual symptom, like sneezing, stuﬃ   ness,  itching, 
runny nose, cough, postnasal drip, facial pain, and 
headache, was also signiﬁ  cantly improved in the R112 
group compared with control treatment. Th  e most 
important feature of R112 was noted to be the rapid 
onset of action. Within 45 minutes, rhinitis symptoms 
were relieved by using R112, and the duration of action 
extended to 4 hours. It appears that larger studies to 
validate the eﬃ   cacy of Syk inhibition in the treatment of 
allergy are in order.
3.4. Syk inhibition in immune thrombocytopenic purpura
In patients with immune thrombocytopenic purpura 
(ITP), there is an accelerated clearance of circulating IgG-
coated platelets through Fcγ receptor-bearing macro-
phages in the spleen and the liver [55]. Syk inhibition 
should limit platelet destruction in patients with ITP, 
probably by blocking FcγR signaling. Injection of mice 
with an antibody directed to integrin αIIb leads to 
profound thrombocytopenia, which is prevented in mice 
pretreated with R788 [56]. Also, pretreatment with Syk 
inhibitors prevented anemia in a mouse model of auto-
immune hemolytic anemia (AHA) [56]. At the clinical 
level, treatment of a small number of patients (n = 12) 
suﬀ   ering from ITP with an R406 led to therapeutic 
success. Speciﬁ  cally, in 8 patients, the clinical response 
was sustained, whereas in the remaining 4, the response 
was of limited duration. Obviously, larger studies are 
needed to determine clinical eﬃ   cacy.
3.5. Syk inhibitors in intestinal ischemia reperfusion injury
Because hematopoietic cells are involved in the expres-
sion of intestinal ischemia-reperfusion injury (IRI), we 
investigated the ability of R788 to protect mice against 
Table 2. Spleen tyrosine kinase inhibition therapy in lupus animal models
Reference Drug  Duration  Model  Outcome
Bahjat et al. [50]  R788  24 to 34 weeks, 20 to   Lupus-prone mice (NZB/NZW)  Delayed proteinuria and kidney dysfunction and prolonged
    40 mg/kg twice daily,     survival
   orally   
Deng et al. [52]  R788  3 to 10 g/kg of diet,   Lupus-prone mice (MRL/lpr and  Decreased skin and renal disease
    up to 16 weeks, orally  BAX/BAK) 
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day) for 6 days before intestinal IRI was performed. We 
observed that R788 signiﬁ  cantly suppressed both local 
intestinal and remote lung injury. Th  e beneﬁ  cial eﬀ  ect 
was associated with reduced IgM and complement 3 
deposition to the aﬀ  ected tissues and signiﬁ  cant reduc-
tion of polymorphonuclear cell inﬁ   l tra tion.  Th   e value of 
this study is that it extends the clinical range of the 
therapeutic value of Syk inhibitors to conditions involving 
IRI, such as organ transplant and coronary and carotid 
revascularization.
3.6. Syk signaling in autoinfl  ammatory disorders
Recent studies have revealed essential roles for Syk in the 
inﬂ   ammasome production of cytosolic Nlrp3 (NLR 
family pyrin domain-containing 3) [58,59]. Syk signaling 
is important for the production of reactive oxygen species 
and gene transcription factors important in the expres-
sion of pro  inﬂ   am ma tory  factors  like  IL-1β.  Pro-IL-1β 
synthesis is regulated by the Syk-caspase recruitment 
domain 9 (Syk-Card9) pathway (Figure 6) [58].
Nlrp3 inﬂ  ammasome has been shown to be involved in 
monosodium urate (MSU)-mediated activation of mono-
cytes [60]. It was reported that the MSU-triggered inﬂ  am-
matory response requires Nlrp3 and adaptor protein 
apoptosis-associated speck-like protein contain  ing Card 
[61]. MSU causes strong Syk tyrosine phos  phorylation in 
human neutrophils, which can be suppressed in the 
presence of piceatannol [62]. Apparently, Syk is required 
for MSU-mediated activated protein kinase activation 
and IL-1β production, and Syk recruitment leads to 
Card9 activation, which controls pro-IL-1β synthesis 
(Figure 6) [58,60,61]. Card9 has been known to mediate 
events downstream of Syk in ITAM-mediated activation 
[63]. Th   ese studies have generated a rationale for the use 
of Syk inhibitors in the treatment of crystal-induced 
arthritis and other autoinﬂ  ammatory diseases.
4. Conclusions and future directions
Syk, initially recognized as a critical signaling molecule in 
mast cells and lymphocytes, has been documented to be 
important in the function of additional cells like platelets, 
monocytes, macrophages, and osteoclasts. As all of these 
cells are involved in the instigation and establishment of 
tissue pathology in autoimmune allergic and auto  inﬂ  am-
matory diseases, Syk inhibition has gained signiﬁ  cant 
interest as an important therapeutic tool.
Preclinical evidence argues convincingly that patients 
suﬀ  ering from diseases such as RA, SLE, ITP, and AHA 
and allergic rhinitis stand a good chance to beneﬁ  t from 
Syk inhibition. Interestingly, reperfusion injury, which 
follows ischemia in mice, is greatly suppressed by Syk 
inhibitors, extending the range of diseases with possible 
clinical beneﬁ  t to organ transplantation and revascu  lari-
zation procedures. Th  e clinical experience is limited to 
patients with RA and ITP. Yet the rapidity of action and 
the extent of clinical improvement call for further clinical 
trials.
Obviously, there are serious questions that need 
attention. Is Syk involved in the function of additional 
cells? What other kinases or non-kinase molecules are 
targeted by the available Syk inhibitors? Can medicinal 
chemistry enable the development of inhibitors that are 
more speciﬁ  c? Th   e RA trial noted several, albeit manage-
able, side eﬀ  ects. Do the noted side eﬀ  ects hint at addi-
tional unrecognized target molecules aﬀ  ected by the used 
Syk inhibitor? Do the side eﬀ  ects point to the presence of 
Syk in additional cells (for example, intestinal epithelial 
cells). Th   e recorded hypertension in patients treated with 
the Syk inhibitor needs special consideration.
We believe that now that Syk inhibitors have earned a 
place in the line of drugs to be further developed for 
clinical use, eﬀ  ort should be invested to further under-
stand the mechanism of inhibition of Syk enzymatic 
activity in an eﬀ  ort to derive compounds with increased 
Table 3. Spleen tyrosine kinase inhibition therapy in allergic infl  ammatory disease models
Reference Drug  Duration  Model  Outcome
Seow   Piceatannol  In vitro  Ovalbumin-induced anaphylaxis in  Prevented histamin and leukotriene release
et al. [40]      guinea pig 
Guyer   R112  One dose,   Drug safety study in volunteers with  Drug is safe, reduced PGD2, no diff  erences in symptoms
et al. [54]    intranasally  allergic rhinitis 
Matsubara   R406  10 days, 5 mL/kg,   Animal allergic asthma in BALB/c  Decreased pulmonary eosinophilia and AHR
et al. [20]    twice a day, orally  mice 
Matsubara   R406  5 days, 30 mg/kg,   AHR in BALB/c mice  Protected from AHR, eosinophilia, and lymphocytosis
et al. [22]    twice a day, orally   
Meltzer   R112  2 days, intranasally  Human seasonal allergic rhinitis  Improved global clinical symptoms
et al. [39]       
Yamamoto   BAY 61-3606  21 days, twice a day,   Antigen induced airway  Suppressed antigen-induced passive cutaneous reaction, 
et al. [41]    orally   infl  ammation in rodents.  bronchoconstriction, bronchial edema, and airway 
       infl   ammation.
AHR, airway hyper-responsiveness.
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controlled by Syk is exempliﬁ  ed by a recent report in 
which a Syk-positive myeloid population of cells stimu-
lates lymphangiogenesis in vivo and disruption of Syk 
among others is associated with inappropriate homing of 
leukocytes [64].
Th   e RA clinical trial noted a prompt clinical improve-
ment in patients receiving background treatment. Can 
Syk inhibitors be used in monotherapy? Does prolonged 
treatment preserve the clinical beneﬁ  t, and if so, for how 
long? Does discontinuance of treatment result in a 
prompt rebound of disease? Do existent erosions heal? 
Th  e current trend in RA trials remains the parallel 
administration of biologics in conjunction with MTX to 
patients who fail MTX. Th   is has led to the development 
of a number of biologics, many of which belong to the 
same category. For example, several anti-TNF biologics 
are already available for the treatment of patients with 
RA. Should Syk inhibitors attain approval for the treat-
ment of RA, an opportunity may arise (provided that the 
cost is not too high) to try them in tandem with the 
biologics or as therapeutic adjuvant to biologics. Should 
trials in patients with SLE, ITP, AHA, or gout be initiated, 
a similar and probably longer list of questions should be 
addressed. Th  e report on the beneﬁ  cial  eﬀ   ect of Syk 
inhibition in IRI begs for additional preclinical studies to 
determine the role of Syk inhibition in organ transplant 
and other models of IRI, such as muscle, heart, and liver.
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Figure 6. Mechanisms of monosodium urate (MSU)-mediated infl  ammation and the roles of spleen tyrosine kinase (Syk) and Nlrp3. 
MSU signals activate Nlrp3 infl  ammasome. Syk plays important roles in both pro-IL1β synthesis and Nlrp3 activation in response to MSU. Pro-IL1β 
synthesis occurs through the Syk-Card9 pathway. However, Nlpr3 activation is regulated through a Syk-dependent, mostly Card9-independent 
mechanism. Card9, caspase recruitment domain 9; IL1β, interleukin-1-beta; NF-κB, nuclear factor-kappa-B; Nlrp3, NLR family pyrin domain-
containing 3; SH2, Src homology 2.
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